RECRUITING

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Talk to us

Conditions

Indolent LymphomasLymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaFollicular LymphomaMarginal Zone LymphomaLymphoplasmacytic LymphomaWaldenstrom MacroglobulinemiaCutaneous T Cell Lymphomaexercisedietary intervention

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This health services study will assess a multidisciplinary intervention program directed at fatigue mitigation among patients diagnosed with indolent lymphomas. Specifically, 30 subjects with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 10 subjects with Follicular Lymphoma (FL), marginal zone lymphoma (MZL), lymphoplasmacytic lymphoma (LPL), Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma (CTCL) will be included.

Official Title

Combating Cancer-Related Fatigue: A Personalized Supportive Care Program

Quick Facts

Study Start:2025-06-03
Study Completion:2026-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06860880

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Written informed consent was obtained to participate in the study and HIPAA authorization for the release of personal health information.
  2. * Subjects are willing and able to comply with study procedures based on the judgment of the investigator.
  3. * Age ≥ 18 years at the time of consent.
  4. * Confirmed diagnosis of indolent lymphoma, Waldenström's Macroglobulinemia, or Cutaneous T Cell Lymphoma.
  5. * Significant symptoms of fatigue, as defined by PROMIS Fatigue score \>50.
  1. * Other co-existing malignancies.
  2. * Significant cognitive impairment as defined by Mini-Cog score 0-2 (out of 5) that would prevent understanding of assessments or interventions.
  3. * Unstable or serious illness (e.g., unstable cardiac arrhythmia, severe anemia/thrombocytopenia) that would prevent safe participation in an exercise regimen, per the discretion of the treating physician.
  4. * Individuals who are not able to consume an oral diet, due to swallowing difficulties or other reasons, as this might interfere with the nutritional intervention

Contacts and Locations

Study Contact

Devin McCarthy
CONTACT
(919)-445-4852
devin_mccarthy@med.unc.edu

Principal Investigator

Christopher Jensen, MD MSCR
PRINCIPAL_INVESTIGATOR
UNC Lineberger Comprehensive Cancer Center

Study Locations (Sites)

North Carolina Basnight Cancer Hospital
Chapel Hill, North Carolina, 27514
United States

Collaborators and Investigators

Sponsor: UNC Lineberger Comprehensive Cancer Center

  • Christopher Jensen, MD MSCR, PRINCIPAL_INVESTIGATOR, UNC Lineberger Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-06-03
Study Completion Date2026-12-31

Study Record Updates

Study Start Date2025-06-03
Study Completion Date2026-12-31

Terms related to this study

Keywords Provided by Researchers

  • exercise
  • dietary intervention

Additional Relevant MeSH Terms

  • Indolent Lymphomas
  • Lymphoma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Waldenstrom Macroglobulinemia
  • Cutaneous T Cell Lymphoma